Ocugen (OCGN) Competitors

$1.46 -0.01 (-0.68%)

Closing price 04:00 PM Eastern

Extended Trading

$1.46 0.00 (-0.07%)

As of 05:25 PM Eastern

OCGN vs. MRNA, PFE, RARE, RLAY, and MLYS

Should you buy Ocugen stock or one of its competitors? MarketBeat compares Ocugen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ocugen include Moderna (MRNA), Pfizer (PFE), Ultragenyx Pharmaceutical (RARE), Relay Therapeutics (RLAY), and Mineralys Therapeutics (MLYS). These companies are all part of the "medical" sector.

How does Ocugen compare to Moderna?

Ocugen (NASDAQ:OCGN) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.47M	110.69	-$67.85M	-$0.24	N/A
Moderna	$2.20B	9.01	-$2.82B	-$8.15	N/A

Moderna has a net margin of -143.55% compared to Ocugen's net margin of -1,192.18%. Moderna's return on equity of -26.64% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-127,987.80%	-135.48%
Moderna	-143.55%	-26.64%	-19.32%

Ocugen has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Ocugen currently has a consensus price target of $9.75, suggesting a potential upside of 567.81%. Moderna has a consensus price target of $35.73, suggesting a potential downside of 28.58%. Given Ocugen's stronger consensus rating and higher possible upside, research analysts clearly believe Ocugen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 4.0% of Ocugen shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Moderna had 3 more articles in the media than Ocugen. MarketBeat recorded 33 mentions for Moderna and 30 mentions for Ocugen. Moderna's average media sentiment score of 0.65 beat Ocugen's score of 0.58 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	19 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Ocugen and Moderna tied by winning 8 of the 16 factors compared between the two stocks.

How does Ocugen compare to Pfizer?

Ocugen (NASDAQ:OCGN) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Pfizer had 43 more articles in the media than Ocugen. MarketBeat recorded 73 mentions for Pfizer and 30 mentions for Ocugen. Pfizer's average media sentiment score of 0.82 beat Ocugen's score of 0.58 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	40 Very Positive mention(s)	13 Positive mention(s)	14 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Positive

Ocugen currently has a consensus price target of $9.75, indicating a potential upside of 567.81%. Pfizer has a consensus price target of $28.84, indicating a potential upside of 12.05%. Given Ocugen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ocugen is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Pfizer	3 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.23

Pfizer has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.47M	110.69	-$67.85M	-$0.24	N/A
Pfizer	$62.58B	2.34	$7.77B	$1.31	19.65

Ocugen has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market. Comparatively, Pfizer has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 4.0% of Ocugen shares are owned by company insiders. Comparatively, 0.6% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Pfizer has a net margin of 11.83% compared to Ocugen's net margin of -1,192.18%. Pfizer's return on equity of 19.44% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-127,987.80%	-135.48%
Pfizer	11.83%	19.44%	8.41%

Summary

Pfizer beats Ocugen on 12 of the 17 factors compared between the two stocks.

How does Ocugen compare to Ultragenyx Pharmaceutical?

Ocugen (NASDAQ:OCGN) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

In the previous week, Ocugen had 8 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 30 mentions for Ocugen and 22 mentions for Ultragenyx Pharmaceutical. Ocugen's average media sentiment score of 0.58 beat Ultragenyx Pharmaceutical's score of 0.09 indicating that Ocugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ocugen presently has a consensus price target of $9.75, suggesting a potential upside of 567.81%. Ultragenyx Pharmaceutical has a consensus price target of $60.41, suggesting a potential upside of 134.15%. Given Ocugen's higher probable upside, equities research analysts clearly believe Ocugen is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Ocugen has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ocugen is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.47M	110.69	-$67.85M	-$0.24	N/A
Ultragenyx Pharmaceutical	$670M	3.79	-$575M	-$6.11	N/A

Ocugen has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

10.3% of Ocugen shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 4.0% of Ocugen shares are held by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ultragenyx Pharmaceutical has a net margin of -91.03% compared to Ocugen's net margin of -1,192.18%. Ultragenyx Pharmaceutical's return on equity of -1,024.42% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-127,987.80%	-135.48%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

Summary

Ultragenyx Pharmaceutical beats Ocugen on 10 of the 17 factors compared between the two stocks.

How does Ocugen compare to Relay Therapeutics?

Ocugen (NASDAQ:OCGN) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Relay Therapeutics has a net margin of 0.00% compared to Ocugen's net margin of -1,192.18%. Relay Therapeutics' return on equity of -43.94% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-127,987.80%	-135.48%
Relay Therapeutics	N/A	-43.94%	-40.11%

10.3% of Ocugen shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 4.0% of Ocugen shares are held by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Ocugen had 26 more articles in the media than Relay Therapeutics. MarketBeat recorded 30 mentions for Ocugen and 4 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.87 beat Ocugen's score of 0.58 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocugen presently has a consensus target price of $9.75, suggesting a potential upside of 567.81%. Relay Therapeutics has a consensus target price of $20.56, suggesting a potential upside of 60.84%. Given Ocugen's higher possible upside, analysts clearly believe Ocugen is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Ocugen has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.47M	110.69	-$67.85M	-$0.24	N/A
Relay Therapeutics	$10.68M	229.34	-$276.48M	-$1.57	N/A

Ocugen has a beta of 2.3, indicating that its stock price is 130% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

Summary

Relay Therapeutics beats Ocugen on 11 of the 17 factors compared between the two stocks.

How does Ocugen compare to Mineralys Therapeutics?

Ocugen (NASDAQ:OCGN) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Mineralys Therapeutics has a net margin of 0.00% compared to Ocugen's net margin of -1,192.18%. Mineralys Therapeutics' return on equity of -27.92% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-127,987.80%	-135.48%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

10.3% of Ocugen shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 4.0% of Ocugen shares are held by company insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Ocugen had 7 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 30 mentions for Ocugen and 23 mentions for Mineralys Therapeutics. Ocugen's average media sentiment score of 0.58 beat Mineralys Therapeutics' score of -0.09 indicating that Ocugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mineralys Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ocugen presently has a consensus target price of $9.75, suggesting a potential upside of 567.81%. Mineralys Therapeutics has a consensus target price of $49.33, suggesting a potential upside of 80.91%. Given Ocugen's higher possible upside, analysts clearly believe Ocugen is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Ocugen has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.47M	110.69	-$67.85M	-$0.24	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

Ocugen has a beta of 2.3, indicating that its stock price is 130% more volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

Summary

Ocugen beats Mineralys Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Ocugen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCGN vs. The Competition

Export

Metric	Ocugen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$494.24M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-6.08	18.81	20.87	25.58
Price / Sales	110.69	181.67	521.63	63.56
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	73.00	6.74	9.86	6.70
Net Income	-$67.85M	$24.11M	$3.55B	$333.77M
7 Day Performance	1.39%	0.07%	-0.32%	0.45%
1 Month Performance	-18.89%	0.84%	1.34%	4.06%
1 Year Performance	110.19%	78.10%	41.03%	36.21%

Ocugen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCGN Ocugen	1.7579 of 5 stars	$1.46 -0.7%	$9.75 +567.8%	+109.3%	$494.24M	$4.47M	N/A	80	Trending News Analyst Revision
MRNA Moderna	1.4769 of 5 stars	$47.30 +4.3%	$34.60 -26.8%	+97.8%	$17.92B	$1.94B	N/A	4,700
PFE Pfizer	3.9478 of 5 stars	$26.31 -0.1%	$28.74 +9.2%	+13.5%	$149.72B	$62.58B	19.35	75,000	Trending News Analyst Forecast Analyst Revision
RARE Ultragenyx Pharmaceutical	3.2571 of 5 stars	$24.81 +0.2%	$60.76 +144.9%	-25.3%	$2.44B	$673M	N/A	1,371	Analyst Downgrade Analyst Revision
RLAY Relay Therapeutics	3.0163 of 5 stars	$13.09 +2.9%	$20.56 +57.0%	+367.1%	$2.43B	$15.35M	N/A	330

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCGN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ocugen (OCGN) Competitors

OCGN vs. MRNA, PFE, RARE, RLAY, and MLYS

How does Ocugen compare to Moderna?

Summary

How does Ocugen compare to Pfizer?

Summary

How does Ocugen compare to Ultragenyx Pharmaceutical?

Summary

How does Ocugen compare to Relay Therapeutics?

Summary

How does Ocugen compare to Mineralys Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCGN vs. The Competition

Ocugen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ocugen (OCGN) Competitors

OCGN vs. MRNA, PFE, RARE, RLAY, and MLYS

How does Ocugen compare to Moderna?

Which has stronger earnings and valuation, OCGN or MRNA?

Is OCGN or MRNA more profitable?

Which has more volatility and risk, OCGN or MRNA?

Do analysts rate OCGN or MRNA?

Do insiders & institutionals hold more shares of OCGN or MRNA?

Does the media prefer OCGN or MRNA?

Summary

How does Ocugen compare to Pfizer?

Does the media favor OCGN or PFE?

Do analysts recommend OCGN or PFE?

Which has better valuation & earnings, OCGN or PFE?

Which has more volatility & risk, OCGN or PFE?

Do institutionals & insiders have more ownership in OCGN or PFE?

Is OCGN or PFE more profitable?

Summary

How does Ocugen compare to Ultragenyx Pharmaceutical?

Does the media prefer OCGN or RARE?

Do analysts rate OCGN or RARE?

Which has higher earnings & valuation, OCGN or RARE?

Which has more volatility & risk, OCGN or RARE?

Do institutionals and insiders have more ownership in OCGN or RARE?

Is OCGN or RARE more profitable?

Summary

How does Ocugen compare to Relay Therapeutics?

Is OCGN or RLAY more profitable?

Do insiders & institutionals hold more shares of OCGN or RLAY?

Does the media prefer OCGN or RLAY?

Do analysts recommend OCGN or RLAY?

Which has stronger earnings and valuation, OCGN or RLAY?

Which has more volatility and risk, OCGN or RLAY?

Summary

How does Ocugen compare to Mineralys Therapeutics?

Is OCGN or MLYS more profitable?

Do insiders & institutionals hold more shares of OCGN or MLYS?

Does the media prefer OCGN or MLYS?

Do analysts recommend OCGN or MLYS?

Which has stronger earnings and valuation, OCGN or MLYS?

Which has more volatility and risk, OCGN or MLYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCGN vs. The Competition

Ocugen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools